TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02359162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine :1250mg/m2 (ivdrip) on days 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin :85 mg/m2 (ivdrip) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase : 2500 IU/m2 (intramuscular injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 50 mg/m 2 /day 24 h continuous infusion on days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 0.4 mg/m 2 /day 24 h continuous infusion on days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 10 mg/m 2 /day 24 h continuous infusion on days 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60 mg/m 2 /day 60 mg/m 2 /day on days 1-5

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
Study: NCT03931668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet
Study: NCT04384588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma from COVID-19 donors
Description: Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma from COVID-19 donors
Description: Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma from COVID-19 donors
Description: Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma from COVID-19 donors
Description: Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
Study: NCT05791370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A 12-week parallel dietary intervention
Description: Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A 12-week parallel dietary intervention
Description: Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A 12-week parallel dietary intervention
Description: Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
Study: NCT01489371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study: NCT01411930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine, aripiprazole
Description: 1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole, olanzapine
Description: 1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine
Study: NCT02317146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
Study: NCT00959335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Study: NCT04246255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 10% Oral
Description: 50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul
Description: 50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Study: NCT03706898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg
Study: NCT00388141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDCAP
Description: Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
Study: NCT01526746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg capsule, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg capsule, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg capsule, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg, once
Study: NCT01315743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team COOL
Description: 1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
Study: NCT01526746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg, once
Study: NCT03975647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice per day by mouth (orally)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given twice per day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: 3.6 mg/kg given into the vein (IV; intravenously) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: 3.6 mg/kg given into the vein (IV; intravenously) every 21 days
Study: NCT03451305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow
Description: A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
Study: NCT02953964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: perceptual-based memory encoding training
Description: Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: semantic-based memory encoding training
Description: Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Cognitive stimulation group (control group)
Description: Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
Study: NCT04043104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)
Description: intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
Study: NCT00676962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External facilitation
Description: Study facilitator meets regularly with therapists to aid implementation of CBT
Study: NCT02071654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus P-valve transcatheter implantation
Description: Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
Study: NCT03598764

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic head extraction during Cesarean section
Description: by putting the fingers of the right inside the lower uterine segment to deliver the head

Intervention type: PROCEDURE
Group type: OTHER
Intervention: External pop out technique
Description: The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
Study: NCT00452530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg, administered once daily by subcutaneous injection, for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 2.5 mg, administered twice daily as tablets, for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin-matching placebo
Description: Administered once daily by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban-matching placebo
Description: Oral tablet administered twice daily
Study: NCT02103946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Muscle Plane block (SAM block)
Description: The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
Study: NCT02375256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical buffer solution in which AERAS-402 is formulated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG (1-8 x105 cfu ID)
Description: BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (1-8 x105 cfu ID)
Description: BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
Study: NCT00801255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 500mg po bid/100mg po q8h for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 500mg po bid/100mg po q8h for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg po bid/200mg po q8h for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg/600mg po twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg/900mg po twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg/900mg po twice daily for 14 days
Study: NCT06237764

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT01455844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre (TM)
Description: CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
Study: NCT02746536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow chest compression
Description: During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No slow chest compression
Description: The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air.
Study: NCT01455844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre (TM)
Description: CaPre™ 2.0g daily for 12 weeks
Study: NCT01811563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker
Study: NCT04433793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana).
Study: NCT00329719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT04525183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EOC)
Description: Educational materials
Study: NCT00329719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT04525183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REVITALIZE ACT Intervention
Description: Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REVITALIZE ACT Intervention
Description: Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks